Meeting
2016 Genitourinary Cancers Symposium
A phase 2 study of the Aurora A kinase (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pretreated urothelial cancer (UC).
Authors
Andrea Necchi
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Andrea Necchi , Daniele Raggi , Salvatore Lo Vullo , Luigi Mariani , Patrizia Giannatempo , Giuseppina Calareso , Elena Togliardi , Nicola Nicolai , Federica Perrone , Giuseppe Pelosi , Roberto Salvioni , Filippo G. De Braud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT01653028
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 382)
DOI
10.1200/jco.2016.34.2_suppl.382
Abstract #
382
Poster Bd #
F17
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC).
First Author: Andrea Necchi
Poster
2014 ASCO Annual Meeting
U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).
First Author: Paul M. Barr
Poster
2014 ASCO Annual Meeting
Alliance A091102: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
First Author: Mark Andrew Dickson
Poster
2014 Gastrointestinal Cancers Symposium
Planned interim analysis of phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353.
First Author: Thomas J. George